1. Sanofi, despite the pandemic, sees early gains from CEO Hudson's strategy — Trump administration to require insurers to cover COVID-19 vaccine — Regeneron/Sanofi's Libtayo gets priority review in NSCLC — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

What a joke

Discussion in 'Promius Pharma' started by Anonymous, Jun 13, 2012 at 8:08 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    ---everyone knows the products are just a waste...they do nothing...nothing that really makes a difference. Copy cat...device...just to make the owners rich off our backs trying to see this 'stuff'.

  2. Anonymous

    Anonymous Guest

    "Head" is appropriate for RD. He has a big head and he's good at giving head which is how he got his promotion.
  3. Anonymous

    Anonymous Guest

    with another derm company and RD is a decent guy with a good attitude, someone who you would enjoy working for, not a pharma goofie DM...however, in hearing that he is Head of Sales is at best ridiculous. I knew Promius was a struggling little company with some boring eczema products but a company with a shot to do something, however, RD in any role other than DM is absurd, are the Indians out of there minds?
  4. Anonymous

    Anonymous Guest

    Aqua Pharmaceuticals, LLC Key Developments

    Lupin And Dr. Reddy Reportedly To Acquire Aqua Pharmaceuticals

    Aug 20 12

    Lupin Limited and Dr. Reddy's Laboratories Ltd. are reportedly seeking to acquire Aqua Pharmaceuticals, LLC, sources familiar with the development said. Aqua Pharmaceuticals is valued between $350 million to $400 million and is advised by Deutsche Bank on the sale. Spokesperson for Dr Reddy's said, "Dr Reddy's and Promius Pharma continue to evaluate all the strategic alternatives and viable options as we continue to grow and expand the business." “We keep on evaluating targets, and Lupin would look at inorganic growth wherever we see a strategic fit in keeping with our acquisition policy," a Lupin spokesperson added.